EP3728311A4 - Bispezifische hiv-1-neutralisierende antikörper - Google Patents

Bispezifische hiv-1-neutralisierende antikörper Download PDF

Info

Publication number
EP3728311A4
EP3728311A4 EP18898849.7A EP18898849A EP3728311A4 EP 3728311 A4 EP3728311 A4 EP 3728311A4 EP 18898849 A EP18898849 A EP 18898849A EP 3728311 A4 EP3728311 A4 EP 3728311A4
Authority
EP
European Patent Office
Prior art keywords
neutralizing antibodies
bispecific
hiv
bispecific hiv
neutralizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18898849.7A
Other languages
English (en)
French (fr)
Other versions
EP3728311A1 (de
Inventor
David D. Ho
Yaoxing Huang
Jian Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/850,832 external-priority patent/US10308707B2/en
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of EP3728311A1 publication Critical patent/EP3728311A1/de
Publication of EP3728311A4 publication Critical patent/EP3728311A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP18898849.7A 2017-12-21 2018-12-20 Bispezifische hiv-1-neutralisierende antikörper Pending EP3728311A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/850,832 US10308707B2 (en) 2013-12-02 2017-12-21 Bispecific HIV-1-neutralizing antibodies
PCT/US2018/066643 WO2019135921A1 (en) 2017-12-21 2018-12-20 Bispecific hiv-1-neutralizing antibodies

Publications (2)

Publication Number Publication Date
EP3728311A1 EP3728311A1 (de) 2020-10-28
EP3728311A4 true EP3728311A4 (de) 2021-11-17

Family

ID=67143961

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18898849.7A Pending EP3728311A4 (de) 2017-12-21 2018-12-20 Bispezifische hiv-1-neutralisierende antikörper

Country Status (7)

Country Link
EP (1) EP3728311A4 (de)
JP (1) JP7345861B2 (de)
CN (1) CN111819196B (de)
AU (1) AU2018399587A1 (de)
CA (1) CA3085351A1 (de)
TW (1) TWI745643B (de)
WO (1) WO2019135921A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
CA3230492A1 (en) * 2021-08-30 2023-03-09 Kanglin Biotechnology (Hangzhou) Co., Ltd. Gene sequence construct for gene therapy for hiv infection
WO2024008177A1 (en) * 2022-07-08 2024-01-11 Nanjing Curegene Technology Co., Ltd. Engineered cells and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150152167A1 (en) * 2013-12-02 2015-06-04 Aaron Diamond Aids Research Center Hiv-1-neutralizing antibody potency and breadth via cell receptor anchoring using bispecific antibodies with native architecture

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104955847A (zh) * 2012-12-04 2015-09-30 马里兰州大学(巴尔的摩) HIV-1 Env结合抗体、融合蛋白及其使用方法
WO2016054053A2 (en) * 2014-09-29 2016-04-07 Duke University Hiv-1 antibodies and uses thereof (adcc and bispecific abs)
BR112018008011A2 (pt) * 2015-10-25 2018-10-30 Sanofi proteínas de ligação triespecíficas e/ou trivalentes para prevenção ou tratamento de infecção por hiv

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150152167A1 (en) * 2013-12-02 2015-06-04 Aaron Diamond Aids Research Center Hiv-1-neutralizing antibody potency and breadth via cell receptor anchoring using bispecific antibodies with native architecture

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUANG YAOXING ET AL: "Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity", CELL, ELSEVIER, AMSTERDAM NL, vol. 165, no. 7, 16 June 2016 (2016-06-16), pages 1621 - 1631, XP029612948, ISSN: 0092-8674, DOI: 10.1016/J.CELL.2016.05.024 *

Also Published As

Publication number Publication date
JP2021506945A (ja) 2021-02-22
AU2018399587A1 (en) 2020-07-09
CA3085351A1 (en) 2019-07-11
CN111819196B (zh) 2022-10-28
WO2019135921A1 (en) 2019-07-11
TWI745643B (zh) 2021-11-11
JP7345861B2 (ja) 2023-09-19
CN111819196A (zh) 2020-10-23
TW201938583A (zh) 2019-10-01
EP3728311A1 (de) 2020-10-28

Similar Documents

Publication Publication Date Title
EP3589313A4 (de) Anti-tigit-antikörper
IL279235A (en) DLL3-CD3 bispecific antibodies
EP3569709A4 (de) Anti-gpc3-antikörper
EP3481869A4 (de) Anti-cd73-antikörper
PL3519437T3 (pl) Przeciwciała dwuswoiste przeciwko p95HER2
EP3387442A4 (de) Humanisierte anti-cd73-antikörper
EP3487888A4 (de) Bispezifischer anti-her2-antikörper
EP3334763A4 (de) Neuartige anti-pd-1-antikörper
EP3332006A4 (de) Neuartige anti-pd-l1-antikörper
EP3661558A4 (de) Anti-il1rap-antikörper
EP3242894A4 (de) Anti-pd-l1-antikörper
EP3129055A4 (de) Bispezifische her2-antikörper
EP3307777A4 (de) Neuartige anti-pd-l1-antikörper
EP3606961B8 (de) Garp-tgf-beta-antikörper
EP3380524A4 (de) Humanisierte anti-cll-1-antikörper
EP3684806A4 (de) Neuartige anti-cd3epsilon-antikörper
GB201710838D0 (en) Bispecific antibodies
EP3507307A4 (de) Bispezifische antikörper
EP3512885A4 (de) Anti-pd-1-antikörper
EP3763743A4 (de) Bispezifische antikörper
EP3691447A4 (de) Anti-transthyretin-antikörper
EP3661555A4 (de) Spezifische antikörper und verwendungen davon
EP3617231A4 (de) Anti-gpc-1-antikörper
EP3596126A4 (de) Neuartige anti-trkb-antikörper
EP3377112A4 (de) Chemisch blockierte bispezifische antikörper

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200708

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40036491

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20211014

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/32 20060101ALI20211008BHEP

Ipc: A61K 39/00 20060101ALI20211008BHEP

Ipc: A61P 31/18 20060101ALI20211008BHEP

Ipc: C07K 16/28 20060101ALI20211008BHEP

Ipc: C07K 16/18 20060101ALI20211008BHEP

Ipc: C07K 16/10 20060101AFI20211008BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230314

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230630